Navigation Links
MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
Date:10/26/2007

dImmune continues to reinforce its commitment to developing anti-RSV products with the ongoing development of its next potential anti-RSV antibody, motavizumab, for which the company is planning to submit a Biologic License Application around the beginning of 2008. MedImmune is also developing a small-molecule product candidate to prevent RSV as well as a vaccine against RSV, both of which are in Phase 1 clinical trials.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Synagis(R) (palivizumab)

Synagis is the only monoclonal antibody approved by the FDA to help prevent an infectious disease. Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.

Synagis was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is currently available in 62 countries.

The safety and efficacy of Synagis were established in infants with bronchopulmonary dysplasia, infants with a history of prematurity (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease. The first dose o
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... trends and segments with highest potential revenues Do ... Visiongain,s updated report gives you revenue predictions for ... ahead. For those therapies you find financial data, ... new analysis you get sales forecasts to 2024 ...
(Date:9/30/2014)... Follow us on LinkedIn ... of cholesterol carrier or lipoprotein in the blood. Such ... levels in the body, especially along the walls of ... and other cardiovascular disorders. Cardiovascular Diseases (CVD) is the ... levels on a regular basis, to assess an individual’s ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... Separation (EWS), the high-speed, chemical-free process to clean up ... letter to shareholders, CEO Riggs Eckelberry reported on the ... West Texas, at a site provided by partner ... ramped up to 1000 barrels per day (bpd) and ...
(Date:9/30/2014)... The overall research objective was to ... and use. Most researchers outsource NGS technologies; however, ... within the next 12 months. Data accuracy and ... sequencing instruments. Disease-related research is the dominant use ... to surge, with half of the respondents planning ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Global Next-generation Sequencing Trends 2
... All amounts are in US dollarsQUEBEC CITY, March ... AEZS ; TSX: AEZ), a global biopharmaceutical ... announced the signing of a development, commercialization and ... SNY ) for the development, registration and ...
... as buckyballs may be able to keep the nation,s ... prevent arteries from clogging up. , Engineers at Duke ... bacteria and other microorganisms to accumulate on the membranes ... leads the researchers to believe that coating pipes and ...
... OMAHA, Neb., March 5 Transgenomic, Inc. (OTC ... announced today its Molecular Laboratory has received notification ... offering its services in the state. Transgenomic ... including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology ...
Cached Biology Technology:AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 5Buckyballs could keep water systems flowing 2Buckyballs could keep water systems flowing 3Transgenomic Awarded Clinical Laboratory Certification in California 2Transgenomic Awarded Clinical Laboratory Certification in California 3
(Date:9/30/2014)... HEIGHTS, Ill. (September 30, 2014) People who suffer ... can do to control their asthma besides properly taking ... a new article in the Annals of Allergy, ... American College of Allergy, Asthma and Immunology (ACAAI), asthma ... examining their lifestyle. The woman described in the Annals ...
(Date:9/29/2014)... , coupled with a high-fat diet, may cause animals to ... mBio , the online open-access journal of the American Society ... Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed that mice ... weight when fed a high-fat diet. Mice that did not ... consuming a high-fat diet, and mice that had C. ...
(Date:9/29/2014)... -- Plants have a symbiotic relationship with certain ... nutrients and defend against invaders an important ... vegetables. Now, scientist have discovered that plants may ... ensuring that sprouting plants are colonized from the ... Dame, presented their findings today at the 5th ...
Breaking Biology News(10 mins):Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2Plants prepackage beneficial microbes in their seeds 2
... help transform a key component of disposable cups, ... significantly reducing the environmental impact of this ubiquitous, ... scheduled to appear in the April 1 issue ... Science & Technology . , The microbes, a ...
... Anthropology Jeffrey H. Schwartz and University of Salerno Professor ... New Anatomist journal, shows that the emerging understanding of ... evolution, originally explained in his seminal work, Sudden Origins: ... & Sons, 2000). , In that book, Schwartz hearkens ...
... in less than 0.2% of the 3-billion-base human genome ... human disease. Today, researchers from the Wellcome Trust Sanger ... Research, together with international colleagues report in PLoS Genetics ... well as genes that are unchanged in recent human ...
Cached Biology News:Microbes convert 'Styrofoam? into biodegradable plastic 2Pitt professor's theory of evolution gets boost from cell research 2Pitt professor's theory of evolution gets boost from cell research 3Researchers map of genetic variations implicated in disease 2Researchers map of genetic variations implicated in disease 3
EZ-DeWax is a one-step solution that simultanously removes paraffin from and rehydrates formalin-fixed, paraffin embedded tissue...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
... Lower operational costs. More efficient ... from limited sample volumes. Industry demands ... to using microbore chromatography for routine ... not adequately satisfy the need to ...
The PDS-1000 He Hepta system includes the PDS-1000 He biolistic system and the Hepta adaptor....
Biology Products: